INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models von Liu, Phillip C. C., Koblish, Holly, Wu, Liangxing, Bowman, Kevin, Diamond, Sharon, DiMatteo, Darlise, Zhang, Yue, Hansbury, Michael, Rupar, Mark, Wen, Xiaoming, Collier, Paul, Feldman, Patricia, Klabe, Ronald, Burke, Krista A., Soloviev, Maxim, Gardiner, Christine, He, Xin, Volgina, Alla, Covington, Maryanne, Ruggeri, Bruce, Wynn, Richard, Burn, Timothy C., Scherle, Peggy, Yeleswaram, Swamy, Yao, Wenqing, Huber, Reid, Hollis, Gregory

Volltext

Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib von Silverman, Ian M., Hollebecque, Antoine, Friboulet, Luc, Owens, Sherry, Newton, Robert C., Zhen, Huiling, Feliz, Luis, Zecchetto, Camilla, Melisi, Davide, Burn, Timothy C.

Volltext

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology von Yue, Eddy W, Sparks, Richard, Polam, Padmaja, Modi, Dilip, Douty, Brent, Wayland, Brian, Glass, Brian, Takvorian, Amy, Glenn, Joseph, Zhu, Wenyu, Bower, Michael, Liu, Xiangdong, Leffet, Lynn, Wang, Qian, Bowman, Kevin J, Hansbury, Michael J, Wei, Min, Li, Yanlong, Wynn, Richard, Burn, Timothy C, Koblish, Holly K, Fridman, Jordan S, Emm, Tom, Scherle, Peggy A, Metcalf, Brian, Combs, Andrew P

Volltext

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity von Liu, Xiangdong, Shin, Niu, Koblish, Holly K., Yang, Gengjie, Wang, Qian, Wang, Kathy, Leffet, Lynn, Hansbury, Michael J., Thomas, Beth, Rupar, Mark, Waeltz, Paul, Bowman, Kevin J., Polam, Padmaja, Sparks, Richard B., Yue, Eddy W., Li, Yanlong, Wynn, Richard, Fridman, Jordan S., Burn, Timothy C., Combs, Andrew P., Newton, Robert C., Scherle, Peggy A.

Volltext

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050 von Fridman, Jordan S, Scherle, Peggy A, Collins, Robert, Burn, Timothy C, Li, Yanlong, Li, Jun, Covington, Maryanne B, Thomas, Beth, Collier, Paul, Favata, Margaret F, Wen, Xiaoming, Shi, Jack, McGee, Ryan, Haley, Patrick J, Shepard, Stacey, Rodgers, James D, Yeleswaram, Swamy, Hollis, Greg, Newton, Robert C, Metcalf, Brian, Friedman, Steven M, Vaddi, Kris

Volltext

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis von Mascarenhas, John O, Talpaz, Moshe, Gupta, Vikas, Foltz, Lynda M, Savona, Michael R, Paquette, Ronald, Turner, A Robert, Coughlin, Paul, Winton, Elliott, Burn, Timothy C, O'Neill, Peter, Clark, Jason, Hunter, Deborah, Assad, Albert, Hoffman, Ronald, Verstovsek, Srdan

Volltext

Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors von Koblish, Holly K, Hansbury, Michael J, Bowman, Kevin J, Yang, Gengjie, Neilan, Claire L, Haley, Patrick J, Burn, Timothy C, Waeltz, Paul, Sparks, Richard B, Yue, Eddy W, Combs, Andrew P, Scherle, Peggy A, Vaddi, Kris, Fridman, Jordan S

Volltext

Global Expanded Access Program for Pemigatinib in Patients with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma and Fibroblast Growth Factor Receptor Gene Alte... von Lindley, Anouk, Prager, Gerald, Bitzer, Michael, Burn, Timothy C, Lihou, Christine F, Croft, Elisabeth

Volltext

The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis von Deininger, Michael, Radich, Jerald, Burn, Timothy C., Huber, Reid, Paranagama, Dilan, Verstovsek, Srdan

Volltext

Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor von Wu, Liangxing, Zhang, Colin, He, Chunhong, Qian, Dingquan, Lu, Liang, Sun, Yaping, Xu, Meizhong, Zhuo, Jincong, Liu, Phillip C. C, Klabe, Ronald, Wynn, Richard, Covington, Maryanne, Gallagher, Karen, Leffet, Lynn, Bowman, Kevin, Diamond, Sharon, Koblish, Holly, Zhang, Yue, Soloviev, Maxim, Hollis, Gregory, Burn, Timothy C, Scherle, Peggy, Yeleswaram, Swamy, Huber, Reid, Yao, Wenqing

Volltext

Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells von Liu, Phillip C.C., Liu, Xiangdong, Li, Yanlong, Covington, Maryanne, Wynn, Richard, Huber, Reid, Hillman, Milton, Yang, Gengjie, Ellis, Dawn, Marando, Cindy, Katiyar, Kamna, Bradley, Jodi, Abremski, Kenneth, Stow, Mark, Rupar, Mark, Zhuo, Jincong, Li, Yun-Long, Lin, Qiyan, Burns, David, Xu, Meizhong, Zhang, Colin, Qian, Ding-Quan, He, Chunhong, Sharief, Vaqar, Weng, Lingkai, Agrios, Costas, Shi, Eric, Metcalf, Brian, Newton, Robert, Friedman, Steven, Yao, Wenqing, Scherle, Peggy A., Hollis, Gregory, Burn, Timothy C.

Volltext

Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing von Neumann, Olaf, Burn, Timothy C., Allgäuer, Michael, Ball, Markus, Kirchner, Martina, Albrecht, Thomas, Volckmar, Anna-Lena, Beck, Susanne, Endris, Volker, Goldschmid, Hannah, Lehmann, Ulrich, Seker-Cin, Huriye, Uhrig, Sebastian, Roessler, Stephanie, Budczies, Jan, Fröhling, Stefan, Longerich, Thomas, Wagner, Alex H., Vogel, Arndt, Schirmacher, Peter, Stenzinger, Albrecht, Kazdal, Daniel

Volltext

Isothiazolidinone inhibitors of PTP1B containing imidazoles and imidazolines von Douty, Brent, Wayland, Brian, Ala, Paul J., Bower, Michael J., Pruitt, James, Bostrom, Lori, Wei, Min, Klabe, Ronald, Gonneville, Lucie, Wynn, Richard, Burn, Timothy C., Liu, Phillip C.C., Combs, Andrew P., Yue, Eddy W.

Volltext

Structural Basis for Inhibition of Protein-tyrosine Phosphatase 1B by Isothiazolidinone Heterocyclic Phosphonate Mimetics von Ala, Paul J., Gonneville, Lucie, Hillman, Milton C., Becker-Pasha, Mary, Wei, Min, Reid, Brian G., Klabe, Ronald, Yue, Eddy W., Wayland, Brian, Douty, Brent, Polam, Padmaja, Wasserman, Zelda, Bower, Michael, Combs, Andrew P., Burn, Timothy C., Hollis, Gregory F., Wynn, Richard

Volltext

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers von Zingg, Daniel, Bhin, Jinhyuk, Yemelyanenko, Julia, Kas, Sjors M., Rolfs, Frank, Lutz, Catrin, Lee, Jessica K., Klarenbeek, Sjoerd, Silverman, Ian M., Annunziato, Stefano, Chan, Chang S., Piersma, Sander R., Eijkman, Timo, Badoux, Madelon, Gogola, Ewa, Siteur, Bjørn, Sprengers, Justin, de Klein, Bim, de Goeij-de Haas, Richard R., Riedlinger, Gregory M., Ke, Hua, Madison, Russell, Drenth, Anne Paulien, van der Burg, Eline, Schut, Eva, Henneman, Linda, van Miltenburg, Martine H., Proost, Natalie, Zhen, Huiling, Wientjens, Ellen, de Bruijn, Roebi, de Ruiter, Julian R., Boon, Ute, de Korte-Grimmerink, Renske, van Gerwen, Bastiaan, Féliz, Luis, Abou-Alfa, Ghassan K., Ross, Jeffrey S., van de Ven, Marieke, Rottenberg, Sven, Cuppen, Edwin, Chessex, Anne Vaslin, Ali, Siraj M., Burn, Timothy C., Jimenez, Connie R., Ganesan, Shridar, Wessels, Lodewyk F. A., Jonkers, Jos

Volltext

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study von Vannucchi, Alessandro Maria, Verstovsek, Srdan, Guglielmelli, Paola, Griesshammer, Martin, Burn, Timothy C., Naim, Ahmad, Paranagama, Dilan, Marker, Mahtab, Gadbaw, Brian, Kiladjian, Jean-Jacques

Volltext

Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters von Huber, Reid M, Murphy, Kathleen, Miao, Bowman, Link, John R, Cunningham, Mark R, Rupar, Mark J, Gunyuzlu, Paul L, Haws, Thomas F, Kassam, Altaf, Powell, Francoise, Hollis, Gregory F, Young, Peter R, Mukherjee, Ranjan, Burn, Timothy C

Volltext

Structural Insights into the Design of Nonpeptidic Isothiazolidinone-containing Inhibitors of Protein-tyrosine Phosphatase 1B von Ala, Paul J., Gonneville, Lucie, Hillman, Milton, Becker-Pasha, Mary, Yue, Eddy W., Douty, Brent, Wayland, Brian, Polam, Padmaja, Crawley, Matthew L., McLaughlin, Erin, Sparks, Richard B., Glass, Brian, Takvorian, Amy, Combs, Andrew P., Burn, Timothy C., Hollis, Gregory F., Wynn, Richard

Volltext

The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies von Stubbs, Matthew C, Burn, Timothy C, Sparks, Richard, Maduskuie, Thomas, Diamond, Sharon, Rupar, Mark, Wen, Xiaoming, Volgina, Alla, Zolotarjova, Nina, Waeltz, Paul, Favata, Margaret, Jalluri, Ravi, Liu, Huiqing, Liu, Xuesong Mike, Li, Jun, Collins, Robert, Falahatpisheh, Nikoo, Polam, Padmaja, DiMatteo, Darlise, Feldman, Patricia, Dostalik, Valerie, Thekkat, Pramod, Gardiner, Christine, He, Xin, Li, Yanlong, Covington, Maryanne, Wynn, Richard, Ruggeri, Bruce, Yeleswaram, Swamy, Xue, Chu-Biao, Yao, Wenqing, Combs, Andrew P, Huber, Reid, Hollis, Gregory, Scherle, Peggy, Liu, Phillip C C

Volltext

Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model von Yue, Eddy W, Douty, Brent, Wayland, Brian, Bower, Michael, Liu, Xiangdong, Leffet, Lynn, Wang, Qian, Bowman, Kevin J, Hansbury, Michael J, Liu, Changnian, Wei, Min, Li, Yanlong, Wynn, Richard, Burn, Timothy C, Koblish, Holly K, Fridman, Jordan S, Metcalf, Brian, Scherle, Peggy A, Combs, Andrew P

Volltext